NASDAQ · STOCK

Gilead Sciences

GILD Biotechnology Unknown Updated July 07, 2026
$133.72
52W $107.75 – $157.29
65/100
$168.00B
18.1
0.34
Price History (6M)
AI Committee Verdict
Buy
Conviction: High · 80% agreement · 5 analysts
+15.8%
-6.0%
2.62:1
100%
Executive Summary
5 analysts weighed in with 60% agreement on a bullish lean. Growth Analyst: EPS growing 55.5% YoY. Overall recommendation: BUY.
Executive Summary
5 analysts weighed in with 60% agreement on a bullish lean. Growth Analyst: EPS growing 55.5% YoY. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
  • RSI at or above 70 signals overbought conditions — bearish entry bias.
  • Positive MACD histogram signals bullish momentum.
  • Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
  • RSI is overbought at 72.4 — momentum may be exhausted.
  • Stochastic RSI (89.6) confirms overbought conditions.
  • Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
  • Lower Highs / Lower Lows structure confirms bearish price action.
AI Investment Committee
Committee Consensus As of July 07, 2026
Overall Committee Score
65/100
Agreement
80%
Analysts
5
Conviction
High
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 42.2% shows genuine earnings power backing the valuation
− Price-to-book of 6.7x prices in significant intangible value
Growth Analyst bullish
72 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 55.5% YoY
Technical Analyst neutral
54 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− RSI at 72 is in overbought territory
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 39 articles, 14d)
Open Full Terminal →
Technical Analysis
RSI (14)
72.4
Overbought
MACD Histogram
1.454
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$127.64
Resistance
$157.26
Bollinger %B
1.09
Above Upper Band
Price vs Moving Averages
EMA 9
$130.57 Above
EMA 21
$128.90 Above
EMA 50
$130.26 Above
EMA 200
$128.47 Above
Fundamental Analysis
Valuation
54
Growth
71
Profitability
100
Financial Health
66
Valuation
P/E Ratio 18.1×
P/B Ratio 6.71×
PEG Ratio
Dividend Yield 2.41%
52W High $157.29
52W Low $107.75
Quality & Growth
ROE 4221.0%
ROA 1606.0%
Gross Margin 7935.0%
Operating Margin 3488.0%
Revenue Growth YoY +348.0%
Debt / Equity 1.10
AI Fundamental Assessment
P/E ratio of 18.1 (inexpensive relative to a 15-40x range); Price-to-book of 6.7x; Revenue growth (YoY) of 3.5%; EPS growth (YoY) of 55.5%; Return on equity of 42.2%; Return on assets of 16.1%; Net margin of 31.0%; Gross margin of 79.3%; Current ratio of 1.55 (healthy short-term liquidity); Debt-to-equity of 1.10; Most recent quarter beat estimates by 4.0%; 4 consecutive earnings beats; EPS growth accelerating (-24.7% -> +9.1% QoQ); Analyst estimates falling over recent quarters
Key Risks
  • RSI is overbought at 72.4 — momentum may be exhausted.
  • Stochastic RSI (89.6) confirms overbought conditions.
  • Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
  • Lower Highs / Lower Lows structure confirms bearish price action.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full GILD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile